Cryo-Cell International
CCEL

$6.82

10.53%

Market Cap: $55M

About: Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The Public cord blood banking segment consists of cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from cellular processing and cryogenic storage and it derives revenue from processing and testing fees and storage segment.

Employees: 88

Healthcare Miscellaneous Health & Allied Services

0

Funds holding %

of 6,728 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

0% more funds holding

Funds holding: 14 [Q1] → 14 (+0) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

0% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 4

4.42% less ownership

Funds ownership: 15.49% [Q1] → 11.07% (-4.42%) [Q2]

29% less capital invested

Capital invested by funds: $9.58M [Q1] → $6.82M (-$2.76M) [Q2]

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for CCEL.

See Analyst Rankings

Financial journalist opinion

Cord Blood Banking Leader Cryo-Cell Reports Fiscal Second Quarter 2024 Financial Results

OLDSMAR, Fla.--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the “Company”), the world's first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal second quarter ended May 31, 2024. Financial Results Revenue Consolidated revenues for the second quarter of fiscal 2024 were $8.0 million compared to $7.8 million for the second quarter of fiscal 2023, a 3% increase. The revenues for the second quarter of fiscal 2024 consiste.

Cord Blood Banking Leader Cryo-Cell Reports Fiscal Second Quarter 2024 Financial Results

Cord Blood Banking Leader Cryo-Cell Reports Fiscal First Quarter 2024 Financial Results

OLDSMAR, Fla.--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American LLC: CCEL ) (the “Company”), the world's first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal first quarter ended February 29, 2024. Financial Results Revenue The revenues for the first quarter of fiscal 2024 were $7.85 million compared to $7.82 million for the first quarter of fiscal 2023. The revenues for the first quarter of fiscal 2024 consisted of $7.81 million i.

Cord Blood Banking Leader Cryo-Cell Reports Fiscal First Quarter 2024 Financial Results

Cryo-Cell Announces Plans to Explore Strategic Alternatives and Spin-off Celle Corp. to Maximize Shareholder Value

OLDSMAR, Fla.--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the “Company” or “Cryo-Cell”), the world's first private cord blood bank to separate and store stem cells in 1992, today announced that its Board of Directors has authorized the spin-off of its newly formed subsidiary, Celle Corp., to the Cryo-Cell shareholders and to explore all strategic alternatives for Cryo-Cell (post spin-off) to maximize shareholder value, including, but not limited to, equity and/or.

Cryo-Cell Announces Plans to Explore Strategic Alternatives and Spin-off Celle Corp. to Maximize Shareholder Value

See News Rankings